Huike Wang

Huike Wang

Auto-generated profile, based on publicly available information

Huike Wang

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
HWHui-Ke Wang
Hui-Ke Wang
QWQian Wei
Qian Wei
YYYa-Lan Yang
Ya-Lan Yang
TLTai-Ying Lu
Tai-Ying Lu
YYYan Yan
Yan Yan
FWFeng Wang
Feng Wang
Background: Multiple perioperative inflammatory markers are considered important factors affecting the long-term survival of esophageal cancer (EC) patients. Hematological parameters, whether single or combined, have high predictive value. Aim: To investigate the inflammatory status of patients with preoperative EC using blood inflammatory markers, and to establish and validate competing risk nomogram prediction models for overall survival (OS) and progression-free survival (PFS) in EC patients. Methods: A total of 508 EC patients who received radical surgery (RS) treatment in The First Affiliated Hospital of Zhengzhou University from August 5, 2013, to May 1, 2019, were enrolled and randomly divided into a training cohort (356 cases) and a validation cohort (152 cases). We performed least absolute shrinkage and selection operator (LASSO)-univariate Cox- multivariate Cox regression analyses to establish nomogram models. The index of concordance (C-index), time-dependent receiver operating characteristic (ROC) curves, time-dependent area under curve (AUC) and calibration curves were used to evaluate the discrimination and calibration of the nomograms, and decision curve analysis (DCA) was used to evaluate the net benefit of the nomograms. The relative integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were calculated to evaluate the improvement in predictive accuracy of our new model compared with the AJCC staging system and another traditional model. Finally, the relationship between systemic inflammatory response markers and prognostic survival was explored according to risk plot, time-dependent AUC, Kaplan–Meier and restricted cubic spline (RCS). Results: Based on the multivariate analysis for overall survival (OS) in the training cohort, nomograms with 10 variables, including the aggregate index of systemic inflammation (AISI) and lymphocyte-to-monocyte ratio (LMR), were established. Time-dependent ROC, time-dependent AUC, calibration curves, and DCA showed that the 1-, 3-, and 5 year OS and PFS probabilities predicted by the nomograms were consistent with the actual observations. The C-index, NRI, and IDI of the nomograms showed better performance than the AJCC staging system and another prediction model. Moreover, risk plot, time-dependent AUC, and Kaplan–Meier showed that higher AISI scores and lower LMR were associated with poorer prognosis, and there was a nonlinear relationship between them and survival risk. Conclusion: AISI and LMR are easy to obtain, reproducible and minimally invasive prognostic tools that can be used as markers to guide the clinical treatment and prognosis of patients with EC.

1 April 2023 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YYYalan Yang
Yalan Yang
DXDao Xin
Dao Xin
HWHuike Wang
Huike Wang
LGLulu Guan
Lulu Guan
XMXiangrui Meng
Xiangrui Meng
FWFeng Wang
Feng Wang
Purpose: Neoadjuvant immunochemotherapy (nICT) for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) has attracted widespread attention recently, whose safety and clinical benefit was observed in clinical researches. This study aimed to develop and validate a novel predictor systemic inflammation-tumor markers index (SITI) to predict the pathological complete response (pCR) for resectable LA-ESCC patients receiving nICT. Patients and Methods: A total of 147 LA-ESCC patients who underwent nICT followed by surgery from February 2020 to April 2022 were included in the study. The dynamic change of inflammatory indexes was compared at baseline, after two cycles of nICT and postoperative one month. Least absolute shrinkage and selection operator (LASSO) regression was performed to avoid collinearity and identify key indexes, with SITI constructed. After univariate and multivariate stepwise forward logistic analyses, a nomogram for pCR prediction was developed. Results: 41(27.9%) patients achieved pCR among 147 resectable LA-ESCC patients received nICT. Compared with baseline, most inflammatory indexes were significantly decreased at postoperative one month. 5 key indexes were identified and then a predictive index named SITI was constructed. The result showed that lower SITI and earlier clinical tumor node metastasis (cTNM) stage were more likely to achieve pCR. The nomogram for pCR prediction had excellent discrimination performance (C-index = 0.791). Conclusion: The SITI is an independent predictor for pCR in resectable LA-ESCC patients received nICT. To our knowledge, our nomogram is the first model using systemic inflammation-tumor markers for pCR prediction and may be a promising predictor to effectively differentiate pCR for nICT in LA-ESCC patients.

1 April 2026 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
HTHuijing Tan
Huijing Tan
HWHuike Wang
Huike Wang
JZJianguo Zhou
Jianguo Zhou
LJLiming Jiang
Liming Jiang
SSSusheng Shi
Susheng Shi
YCYihebali Chi
Yihebali Chi
Background: Certain histologic subtypes of advanced soft tissue sarcomas, including alveolar soft part sarcoma (ASPS) and undifferentiated pleomorphic sarcoma (UPS), lack standardized therapeutic options following anthracycline-based first-line therapy. This study was to investigate the efficacy and safety of camrelizumab plus apatinib in advanced unresectable ASPS or UPS. Methods: In this single-center, exploratory case series, patients with ASPS or UPS received a combination of camrelizumab and apatinib. The primary endpoint was the objective response rate (ORR), while the exploratory endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: The median follow-up period was 24.0 months, with an ORR of 88.9% (8/9). In the ASPS subgroup (n=7), neither the median PFS (mPFS) nor median OS (mOS) was reached, while the ORR was 100.0% (7/7). In the UPS subgroup (n=2), the mPFS was 7.5 months and the mOS was 9.5 months, with the ORR of 50.0% (1/2). One patient with ASPS died from immune-mediated myocarditis; all other adverse events (AEs) were grade 1– 2 and manageable with symptomatic treatment. Conclusion: The combination therapy of camrelizumab and apatinib may provide benefits in clinical outcomes for ASPS, while the outcomes in UPS appears more variable, warranting further study. Close monitoring for AEs, especially fatal complications such as immune-mediated myocarditis, is essential. Registration: ClinicalTrials.gov (identifier: NCT04447274), registration date: 23-Jun-2020.

1 April 2026 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
HTHuijing Tan
Huijing Tan
JZJianguo Zhou
Jianguo Zhou
SSSusheng Shi
Susheng Shi
LJLiming Jiang
Liming Jiang
LZLijie Zuo
Lijie Zuo
YCYihebali Chi
Yihebali Chi
Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma with high rates of hematogenous metastasis and recurrent relapse, with a 5-year survival rate of 17.0%. This study evaluated the clinical efficacy of an anthracycline plus temozolomide (ATEM) regimen in advanced LMS and explored the feasibility of dynamic circulating tumor DNA (ctDNA) monitoring for early detection of disease progression. This retrospective study included patients with advanced LMS who received ATEM between September 2018 and December 2024. The efficacy, including complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), objective response rate (ORR), and disease control rate (DCR), as well as safety, were assessed. The median progression-free survival (mPFS) and median overall survival (mOS) were calculated using Kaplan–Meier survival curves. A subset of patients treated with TEM-containing regimens between December 2023 and December 2024 underwent longitudinal ctDNA monitoring. Forty-seven patients were included, with a median follow-up of 39.5 months. The mPFS was 12.0 months and mOS was 37.5 months. One patient achieved clinical CR, 9 achieved PR, 33 had SD and 4 experienced PD. The ORR was 21.3% (10/47), and DCR was 91.5% (43/47). The most common adverse events were leukopenia (42.6%), neutropenia (32.0%), and thrombocytopenia (14.9%). Grade 4 neutropenia occurred in three patients, including one case complicated by febrile neutropenia. All cases were managed successfully with supportive treatment. No treatment-related deaths were observed. In this pilot investigation of 7 patients, ctDNA levels consistently reflected clinical disease status and treatment response. ATEM regimen demonstrated promising efficacy in advanced LMS, with survival outcomes comparable to or better than in prior first-line treatments. ctDNA monitoring showed promise as a non-invasive biomarker for disease monitoring and treatment guidance. Prospective, multi-center studies are warranted to validate these findings.

1 May 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HTHuijing Tan
Huijing Tan
HWHuike Wang
Huike Wang
YSYuting Sun
Yuting Sun
JYJianming Ying
Jianming Ying
YCYihebali Chi
Yihebali Chi
Background: Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma, with the liver and lungs as the predominant primary sites. To date, no standard systemic therapy has been established for advanced EHE. This study aimed to evaluate the efficacy and safety of everolimus in patients with advanced, unresectable, and progressive EHE. Methods: This case series retrospectively included 11 patients with advanced, progressive EHE who received systemic therapy with everolimus at our hospital spanning a 3-year period. The clinical outcomes, including time to treatment failure (TTF), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs), were analyzed. The median follow-up time was estimated using the reverse Kaplan–Meier method. Results: At the data cutoff (April 11, 2025), the median follow-up time was 21.9 months. The median TTF was 21.3 months, and median OS was not reached at the time of analysis. All 11 cases achieved stable disease (SD); the ORR was 0% (0/11), and the DCR was 100.0% (11/11). The most common AEs were mucositis accompanied by multiple oral ulcers (54.5%), which was limited to grade 1– 2 severity. One patient (9.1%) experienced grade 3 upper gastrointestinal bleeding. Other AEs included interstitial pneumonia (27.3%), rash (18.2%), and thrombocytopenia (18.2%). No grade 4 or 5 AEs were observed. Conclusion: Everolimus showed preliminary activity, primarily disease stabilisation, in this small retrospective case series of patients with advanced, unresectable, and progressive EHE. Further studies with larger cohorts are warranted to validate these findings.